Protagonist CFO Ali Asif sells $8.3 million in company stock

Chief Financial Officer Ali Asif of Protagonist Therapeutics (NASDAQ:PTGX) sold 58,629 shares of the company's stock on September 30, 2026, for $8.3 million. The sale occurred as the stock price declined by over 10% in the previous week. Despite this recent decline, shares have increased by 66% over the past year. The company appears overvalued according to InvestingPro, which offers 18 additional ProTips for evaluating Protagonist Therapeutics.

Mr. Asif exercised stock options to acquire the shares, with prices ranging from $12.17 to $38.98 per share. His transactions were executed through a Rule 10b5-1 trading plan adopted in June 2026. Following the sale, Mr. Asif holds a total of 59,003 shares of Protagonist Therapeutics common stock. In other news, the company received positive developments, including FDA approval of Mimrylo for treating erythrocytosis in adults with polycythemia vera.

This approval marks Protagonist's second consecutive regulatory win, following the approval of Icotyde earlier this year. Analysts have expressed growing confidence in Protagonist Therapeutics' market potential, with several firms raising their price targets and setting Buy ratings.